PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that three poster presentations will be presented from the recently completed Phase I trial for its product candidate AR-67, formerly known as DB-67, a small molecule third generation camptothecin, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, FL, from May 29 to June 2, 2009.
